Medigen Vaccine Biologics's Days Sales Outstanding for the
three
months ended in Dec. 2025 was 88.69.
Medigen Vaccine Biologics's Days Inventory for the
three
months ended in Dec. 2025 was 977.42.
Medigen Vaccine Biologics's Days Payable for the
three
months ended in Dec. 2025 was 24.88.
Therefore, Medigen Vaccine Biologics's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2025 was 1,041.23.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Medigen Vaccine Biologics Cash Conversion Cycle Related Terms
Medigen Vaccine Biologics Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6547 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Medigen Vaccine Biologics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Vaccine Biologics Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Medigen Vaccine Biologics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Medigen Vaccine Biologics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of 1,041.23 mean?
Medigen Vaccine Biologics (ROCO:6547) has a Cash Conversion Cycle of 1,041.23 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medigen Vaccine Biologics and its competitors.
Is Medigen Vaccine Biologics' Cash Conversion Cycle too high?
Medigen Vaccine Biologics' current Cash Conversion Cycle is 1,041.23. The Biotechnology industry median Cash Conversion Cycle is 104.03. Medigen Vaccine Biologics' value of 1,041.23 is 900.9% above this industry median. Overall, Medigen Vaccine Biologics has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Cash Conversion Cycle compare to VRTX and REGN?
Medigen Vaccine Biologics' Cash Conversion Cycle of 1,041.23 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 104.03. Medigen Vaccine Biologics' value of 1,041.23 is 900.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 104.03, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Vaccine Biologics's current Cash Conversion Cycle of 1,041.23 is 900.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medigen Vaccine Biologics and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Vaccine Biologics's current Cash Conversion Cycle is 1,041.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.34, compared to a current price of NT$47.50 — trading 32.5% below its estimated fair value. The current Cash Conversion Cycle is 1,041.23 and 900.9% above the Biotechnology industry median of 104.03. Medigen Vaccine Biologics' overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Cash Conversion Cycle is 1,041.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued.
The current stock price of NT$47.50 is trading 32.5% below its estimated GF Value™ of NT$70.34.
GuruFocus considers Medigen Vaccine Biologics to be Possible Value Trap.
Key valuation signals for ROCO:6547:
Cash Conversion Cycle: 1,041.23
GF Value™: NT$70.34 vs. price of NT$47.50 (32.5% below fair value)
Industry Position: 900.9% above the Biotechnology median
No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
66GF Score
Get the complete analysis for ROCO:6547
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6547 has been successfully added to your 
